Jazz Non Current Liabilities Other from 2010 to 2025

JAZZ Stock  USD 120.56  3.20  2.59%   
Jazz Pharmaceuticals Non Current Liabilities Other yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Other will likely drop to about 108.3 M in 2025. During the period from 2010 to 2025, Jazz Pharmaceuticals Non Current Liabilities Other regression line of annual values had r-squared of  0.41 and arithmetic mean of  88,968,954. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2012-03-31
Previous Quarter
99.4 M
Current Value
111 M
Quarterly Volatility
56.9 M
 
Yuan Drop
 
Covid
Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 349.5 M, Other Operating Expenses of 3.9 B or Operating Income of 698.6 M, as well as many indicators such as Price To Sales Ratio of 2.22, Dividend Yield of 0.0 or PTB Ratio of 2.98. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Latest Jazz Pharmaceuticals' Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of Jazz Pharmaceuticals PLC over the last few years. It is Jazz Pharmaceuticals' Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
       Timeline  

Jazz Non Current Liabilities Other Regression Statistics

Arithmetic Mean88,968,954
Geometric Mean57,086,253
Coefficient Of Variation68.95
Mean Deviation48,283,091
Median106,812,000
Standard Deviation61,341,324
Sample Variance3762.8T
Range212.3M
R-Value0.64
Mean Square Error2379.9T
R-Squared0.41
Significance0.01
Slope8,246,800
Total Sum of Squares56441.4T

Jazz Non Current Liabilities Other History

2025108.3 M
2024120.5 M
2023104.8 M
2022106.8 M
2021117 M
2020101.1 M
2019109.4 M

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Other120.5 M108.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.